Product data sheet



MedKoo Cat#: 526595		
Name: Nicorandil		
CAS: 65141-46-0		NI.
Chemical Formula: C ₈ H ₉ N ₃ O ₄		
Exact Mass: 211.0593		[´ H
Molecular Weight: 211.177		\mathbb{N} \mathbb{N} \mathbb{N} \mathbb{N}
Product supplied as:	Powder	
Purity (by HPLC): $\geq 98\%$		Ц
Shipping conditions	Ambient temperature	
Storage conditions:	Powder: -20°C 3 years; 4°C 2 years.	
	In solvent: -80°C 3 months; -20°C 2 weeks.	

1. Product description:

Nicorandil is a potassium-channel opener, stimulating apurinic/apyrimidinic endonuclease 1 (APE1) endonuclease activity by increasing catalytic efficiency approximately 2-fold.

2. CoA, QC data, SDS, and handling instruction

SDS and handling instruction, CoA with copies of QC data (NMR, HPLC and MS analytical spectra) can be downloaded from the product web page under "QC And Documents" section. Note: copies of analytical spectra may not be available if the product is being supplied by MedKoo partners. Whether the product was made by MedKoo or provided by its partners, the quality is 100% guaranteed.

3. Solubility data

Solvent	Max Conc. mg/mL	Max Conc. mM
DMSO	28.33	134.17
Ethanol	42.0	198.89
Water	18.5	87.60

4. Stock solution preparation table:

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	4.74 mL	23.68 mL	47.36 mL
5 mM	0.95 mL	4.74 mL	9.47 mL
10 mM	0.47 mL	2.37 mL	4.74 mL
50 mM	0.10 mL	0.47 mL	0.95 mL

5. Molarity Calculator, Reconstitution Calculator, Dilution Calculator

Please refer the product web page under section of "Calculator"

6. Recommended literature which reported protocols for in vitro and in vivo study

In vitro study

- 1. Akao M, Teshima Y, Marbán E. Antiapoptotic effect of nicorandil mediated by mitochondrial atp-sensitive potassium channels in cultured cardiac myocytes. J Am Coll Cardiol. 2002 Aug 21;40(4):803-10. doi: 10.1016/s0735-1097(02)02007-7. PMID: 12204514.
- 2. Sato T, Sasaki N, O'Rourke B, Marbán E. Nicorandil, a potent cardioprotective agent, acts by opening mitochondrial ATP-dependent potassium channels. J Am Coll Cardiol. 2000 Feb;35(2):514-8. doi: 10.1016/s0735-1097(99)00552-5. PMID: 10676702.

In vivo study

- 1. Liu Y, Shu J, Liu T, Xie J, Li T, Li H, Li L. Nicorandil protects against coronary microembolization-induced myocardial injury by suppressing cardiomyocyte pyroptosis via the AMPK/TXNIP/NLRP3 signaling pathway. Eur J Pharmacol. 2022 Dec 5;936:175365. doi: 10.1016/j.ejphar.2022.175365. Epub 2022 Nov 3. PMID: 36336011.
- 2. Horinaka S, Kobayashi N, Higashi T, Hara K, Hara S, Matsuoka H. Nicorandil enhances cardiac endothelial nitric oxide synthase expression via activation of adenosine triphosphate-sensitive K channel in rat. J Cardiovasc Pharmacol. 2001 Aug;38(2):200-10. doi: 10.1097/00005344-200108000-00005. PMID: 11483869.

Product data sheet



7. Bioactivity

Biological target:

Nicorandil (SG-75) is a potent potassium channel activator and targets vascular nucleoside diphosphate-dependent K^+ channels and cardiac ATP-sensitive K^+ channels ($K_{\rm ATP}$).

In vitro activity

Nicorandil (100 micromol/liter) increased flavoprotein oxidation but not membrane current; a 10-fold higher concentration recruits both mitoK(ATP) and surfaceK(ATP) channels. Nicorandil blunted the rate of cell death in a pelleting model of ischemia; this cardioprotective effect was prevented by the mitoK(ATP) channel blocker 5-hydroxydecanoate but was unaffected by the surfaceK(ATP) channel blocker HMR1098.

Reference: J Am Coll Cardiol. 2000 Feb;35(2):514-8. https://pubmed.ncbi.nlm.nih.gov/10676702/

In vivo activity

This study's aim was to assess whether pharmacologic activation of the K(ATP) channel by nicorandil contributes to endothelial nitric oxide synthase (eNOS) levels. A total of 21 7-week old male Sprague-Dawley rats were used. Nicorandil caused tachycardia without a change in blood pressure, whereas glibenclamide had no effect on the nicorandil-induced change in heart rate or on blood pressure. RT-PCR revealed that nicorandil increased the eNOS and SUR2 mRNA levels by 2.2- and 2.0-fold, respectively, (p < 0.01 versus control), and that these increases were completely inhibited by glibenclamide.

Reference: J Cardiovasc Pharmacol. 2001 Aug;38(2):200-10. https://pubmed.ncbi.nlm.nih.gov/11483869/

Note: The information listed here was extracted from literature. MedKoo has not independently retested and confirmed the accuracy of these methods. Customer should use it just for a reference only.